Established in 1994, Stason Pharmaceuticals, Inc. started as a generic drug manufacturer, and today—while venturing into IND development—continues to manufacture and market these products through our global network of distributors.
Stason entered the contract development & manufacturing arena in 2000. As a CDMO, Stason provides product development and manufacturing support to other pharmaceutical companies. Our specialty is high containment manufacturing at commercial scales.
In 2008, we launched our Brand Division when we obtained exclusive development and commercialization rights to novel proprietary compounds in the area of oncology. For more information click here
In 2014, we established our sales & marketing division, which has captured a significant market share for each product. We expect to launch several products per year, including authorized generics, injectables, and 505(b)(2)s.
Ongoing expansion projects include: the establishment of dedicated business development offices in the US & Canada, laboratories in Kansas, a logistics center for distribution in North America, launch of consumer healthcare division, and construction of a pilot plant for expansion of our product development capabilities.